Syntheses of dual-radioisotope-labeled CP-I, a GABAA receptor partial agonist
作者:Yinsheng Zhang、Laura Greenfield、Yang Hong
DOI:10.1002/jlcr.1889
日期:2011.6.30
of CP-I labeled at the right or left hand side with 14C or labeled with 3H at the right hand side were required. The two compounds labeled with 14C at the left or right hand side were synthesized in 2 and 5 radio-synthetic steps using [14C]2-chloroacetyl chloride and [14C]NaCN as starting radiolabeled materials, respectively. CP-I was labeled with tritium at the right hand side by a tritium de-halogenation
It is intended to provide novel amine compounds which are efficacious against diseases such as infection with HIV virus, rheumatism and cancer metastasis. Namely, amine compounds represented by the following general formula (1):
In a typical case, A1 and A2 represent each an optionally substituted monocyclic or polycyclic aromatic heterocycle; W represents cyclic C3-10 alkylene, an optionally substituted monocyclic or polycyclic aromatic heterocycle, a monocyclic or polycyclic aromatic ring or a partly saturated polycyclic aromatic ring; X represents O, CH2, C(═O) or NR11; and D is a group represented by the following general formula (4) or (6).
In the formula (6), Q represents a single bond, S, O or NR12; and Y is a group represented by the following general formula (7).
z represents an optionally substituted monocyclic or polycyclic aromatic ring. In the formula (6), B represents NR25R26. In the above formulae, R1 to R26 each represents hydrogen, alkyl, alkenyl or alkynyl.
This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I
The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABA
A
receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed.
This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABA
A
receptors in tissue sections.
It is intended to provide novel amine compounds which are efficacious against diseases such as infection with HIV virus, rheumatism and cancer metastasis. Namely, amine compounds represented by the following general formula (1):
In a typical case, A1 and A2 represent each an optionally substituted monocyclic or polycyclic aromatic heterocycle; W represents cyclic C3-10 alkylene, an optionally substituted monocyclic or polycyclic aromatic heterocycle, a monocyclic or polycyclic aromatic ring or a partly saturated polycyclic aromatic ring; X represents O, CH2, C(═O) or NR11; and D is a group represented by the following general formula (4) or (6).
In the formula (6), Q represents a single bond, S, O or NR12; and Y is a group represented by the following general formula (7).
z represents an optionally substituted monocyclic or polycyclic aromatic ring. In the formula (6), B represents NR25R26. In the above formulae, R1 to R26 each represents hydrogen, alkyl, alkenyl or alkynyl.
Novel amine compounds which are represented by the following formula (1) and efficacious against diseases such as a viral infectious disease with HIV, rheumatism, and cancer metastasis;
typically, A
1
and A
2
represent a hydrogen atom or a substitutable monocyclic or polycyclic heteroaromatic ring and W represents a substitutable benzene ring or any group represented by the following formula (10) or (11):
where
X represents O, CH
2
, C(═O), NR
11
, or CHR
35
and D represents a group represented by the following formula (6):
where
Q represents a single bond, NR
12
, or a group represented by the formula (13):
and Y represents a group represented by the following formula (7):
where z represents a substitutable monocyclic or polycyclic aromatic ring; and
B represents —NR
25
R
26
; and R
1
to R
26
in the above formulae represent a hydrogen atom, an alkyl group, an alkenyl group, or an alkynyl group.